These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37925551)

  • 21. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
    Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
    Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
    Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".
    Lee Y; Uhm JE; Lee HY; Park MJ; Kim H; Oh SJ; Jang JH; Kim K; Jung CW; Ahn YC; Park K; Ko YH; Kim WS
    Ann Hematol; 2009 Feb; 88(2):111-9. PubMed ID: 18648812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL).
    Cottereau AS; Becker S; Broussais F; Casasnovas O; Kanoun S; Roques M; Charrier N; Bertrand S; Delarue R; Bonnet C; Hustinx R; Gaulard P; de Leval L; Vera P; Itti E; Mounier N; Haioun C; Tilly H; Meignan M
    Ann Oncol; 2016 Apr; 27(4):719-24. PubMed ID: 26787236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central nervous system involvement in T-cell lymphoma: A single center experience.
    Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
    Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive model for treatment outcomes of peripheral T-cell lymphoma, not otherwise specified, in Taiwanese patients.
    Chen NC; Chang H; Kuo MC; Lin TL; Shih LY; Chuang WY; Kao HW
    J Formos Med Assoc; 2024 Feb; 123(2):188-197. PubMed ID: 37558588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan.
    Tokunaga T; Shimada K; Yamamoto K; Chihara D; Ichihashi T; Oshima R; Tanimoto M; Iwasaki T; Isoda A; Sakai A; Kobayashi H; Kitamura K; Matsue K; Taniwaki M; Tamashima S; Saburi Y; Masunari T; Naoe T; Nakamura S; Kinoshita T
    Blood; 2012 Mar; 119(12):2837-43. PubMed ID: 22308294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
    Rüdiger T; Weisenburger DD; Anderson JR; Armitage JO; Diebold J; MacLennan KA; Nathwani BN; Ullrich F; Müller-Hermelink HK;
    Ann Oncol; 2002 Jan; 13(1):140-9. PubMed ID: 11863096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis.
    Tolkachjov SN; Weenig RH; Comfere NI
    J Am Acad Dermatol; 2016 Nov; 75(5):992-999. PubMed ID: 27498959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 25-Hydroxy vitamin D deficiency is an inferior predictor of peripheral T-cell lymphomas.
    Shen HR; Tang J; Li WY; Liang JH; Li Y; Wu JZ; Wang L; Li JY; Gao R; Yin H; Xu W
    Ann Hematol; 2024 Feb; 103(2):565-574. PubMed ID: 37951853
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
    Savage KJ; Chhanabhai M; Gascoyne RD; Connors JM
    Ann Oncol; 2004 Oct; 15(10):1467-75. PubMed ID: 15367405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
    Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification.
    Kim K; Kim WS; Jung CW; Im YH; Kang WK; Lee MH; Park CH; Ko YH; Ree HJ; Park K
    Eur J Cancer; 2002 Jan; 38(1):75-81. PubMed ID: 11750843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of survivin expression in peripheral T-cell lymphoma].
    Xiang XJ; He YJ; Li YH; Huang H; Xu F
    Ai Zheng; 2006 Jun; 25(6):758-61. PubMed ID: 16764776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis.
    Lim ST; Hee SW; Quek R; Lim LC; Yap SP; Loong EL; Sng I; Tan LH; Ang MK; Ngeow J; Tham CK; Ngo L; Tan MH; Tao M
    Eur J Haematol; 2008 Jan; 80(1):55-60. PubMed ID: 18028433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western Australia.
    Kuzich JA; Hutchison AP; Lim KJC; Smallbone P; Denning K; Wright MP; Cull G; Leahy MF; Joske DJL; Radeski D; Purtill D
    Leuk Lymphoma; 2019 Dec; 60(14):3417-3425. PubMed ID: 31304820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
    Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
    Front Immunol; 2022; 13():835103. PubMed ID: 35185926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.
    Weisenburger DD; Savage KJ; Harris NL; Gascoyne RD; Jaffe ES; MacLennan KA; Rüdiger T; Pileri S; Nakamura S; Nathwani B; Campo E; Berger F; Coiffier B; Kim WS; Holte H; Federico M; Au WY; Tobinai K; Armitage JO; Vose JM;
    Blood; 2011 Mar; 117(12):3402-8. PubMed ID: 21270441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.